BioCatalystWatch
HELPWorkspace / HELP / OverviewCompany library
Price
Market cap
Next catalystExpected Q4 2026HLP003 — Phase 3 PARADIGM programme · Phase 3 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

HLP003

5-HT2A

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

HLP004

PreINDP1P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

HLP003

5-HT2A

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

HLP004

PreINDP1P3FilingApproved
Upcoming / outlook

Other pipelines

HLP004

PreINDP1P2P3FilingApproved
SPL028

PreINDP1P2P3FilingApproved
SPL028

PreINDP1P2P3FilingApproved
CYB002

PreINDP1P2P3FilingApproved

History / paused

HLP004

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved
HLP003

5-HT2A

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Reported shares and borrowings

Ownership and institutions

Market Reaction / Supply Context

Market Structure

HELP PR & News

PR & News

HELP SEC archive